EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
A phase 3 trial of Afatinib, Dacomitinib and Osimertinib in Non-small-cell lung cancer, run by Region Skane, now recruiting.
Overview
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study is a phase 3 interventional study registered as NCT06486142 by Region Skane, with 200 participants planned, started 2022-09-21 and due to reach its primary completion in 2028-09. Interventions recorded: Afatinib/Dacomitinib, Osimertinib. Conditions recorded: Non-Small Cell Lung Cancer.
Linked to the drug Dacomitinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
Shares Dacomitinib, Non-small-cell lung cancer and the tag pipeline.
- TrialARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC
Shares Dacomitinib, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialJMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialQuaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialOleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.